Insmed (NASDAQ:INSM) Insider Michael Alexander Smith Sells 6,149 Shares of Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 6,149 shares of the stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $108.47, for a total value of $666,982.03. Following the completion of the sale, the insider owned 41,613 shares of the company’s stock, valued at $4,513,762.11. This trade represents a 12.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Alexander Smith also recently made the following trade(s):

• On Monday, March 30th, Michael Alexander Smith sold 19,638 shares of Insmed stock. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24.

Insmed Stock Down 3.0%

Shares of Insmed stock opened at $106.24 on Friday. Insmed, Inc. has a 1 year low of $65.56 and a 1 year high of $212.75. The business has a 50-day moving average of $137.89 and a two-hundred day moving average of $160.87. The company has a market capitalization of $23.03 billion, a P/E ratio of -18.48 and a beta of 0.89. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same period in the prior year, the company earned ($1.42) earnings per share. The company’s revenue for the quarter was up 229.7% compared to the same quarter last year. As a group, equities analysts predict that Insmed, Inc. will post -2.52 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of INSM. CIBC Private Wealth Group LLC boosted its position in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 53 shares during the last quarter. CoreCap Advisors LLC acquired a new position in Insmed during the fourth quarter valued at approximately $27,000. SBI Securities Co. Ltd. boosted its position in Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 166 shares during the last quarter. GraniteShares Advisors LLC acquired a new position in Insmed during the fourth quarter valued at approximately $30,000. Finally, Reflection Asset Management acquired a new position in Insmed during the fourth quarter valued at approximately $30,000.

Analysts Set New Price Targets

INSM has been the subject of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Tuesday, April 21st. Leerink Partners increased their price target on Insmed from $210.00 to $215.00 and gave the stock an “outperform” rating in a report on Tuesday, March 24th. Bank of America increased their price target on Insmed from $211.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. Wells Fargo & Company reduced their price objective on Insmed from $177.00 to $160.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Finally, Stifel Nicolaus upped their price objective on Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a research report on Tuesday, March 24th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Insmed has an average rating of “Moderate Buy” and an average target price of $210.95.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.